Associated Papers
Phenotypic POLE Variant Classification Identifies Patients Who May Have Favorable Prognosis and Benefit from Immunotherapy.
Keller-Evans RB et al.
The Journal of Molecular Diagnostics : Jmd, 2026
Preanalytical Histology Review Improves POLE Mutation Detection in Endometrial Carcinomas.
Huang H et al.
The Journal of Molecular Diagnostics : Jmd, 2026
Comparative Analysis of Somatic and Germline Polymerase Proofreading Deficiencies in Cancer: Molecular and Clinical Implications.
Viana-Errasti J et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2025
Comparison between a Luminex-based multiplex kit with a sequence-specific oligonucleotide probe and next-generation sequencing for the detection of POLE oncogenic mutations in endometrial cancer.
Kato MK et al.
Virchows Archiv : an International Journal of Pathology, 2025
Comprehensive Analysis of Human Colorectal Cancers Harboring Polymerase Epsilon Mutations.
Gibson LM et al.
International Journal of Molecular Sciences, 2025
Functions, interactions and prognostic role of POLE: a bioinformatics analysis.
Carvajal-Veloza J et al.
Journal of Gynecologic Oncology, 2025
POLE-mutated endometrial cancer: new perspectives on the horizon?
Fanale D et al.
Frontiers in Oncology, 2025
Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity.
Shah SM et al.
Cancer Research Communications, 2024
DNA polymerase ε and δ variants drive mutagenesis in polypurine tracts in human tumors.
Ostroverkhova D et al.
Cell Reports, 2024
The game-changing impact of POLE mutations in oncology-a review from a gynecologic oncology perspective.
Kögl J et al.
Frontiers in Oncology, 2024
Recommendations for the classification of germline variants in the exonuclease domain of POLE and POLD1.
Mur P et al.
Genome Medicine, 2023
In-silico analysis of TCGA data showing multiple POLE-like favourable subgroups overlapping with TP53 mutated endometrial cancer: Implications for clinical practice in low and middle-income countries.
Das Ghosh D et al.
Gynecologic Oncology Reports, 2023
Endometrial Carcinomas With Subclonal Loss of Mismatch Repair Proteins: A Clinicopathologic and Genomic Study.
Mendoza RP et al.
The American Journal of Surgical Pathology, 2023
Pelvic Carcinosarcoma Showing a Diverse Histology and Hierarchical Gene Mutation with a Common POLE Mutation to Endometrial Endometroid Carcinoma: A Case Report.
Kitazono I et al.
International Journal of Surgical Pathology, 2022
Whole-Exome Sequencing Reveals Clinical Potential of Circulating Tumor DNA from Peritoneal Fluid and Plasma in Endometrial Cancer.
Ju HY et al.
Cancers, 2022
POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy.
Chen YX et al.
Clinical and Translational Medicine, 2021
MET Mutation Is a Potential Therapeutic Target for Advanced Endometrial Cancer.
Yeh YM et al.
Cancers, 2021
Endometrial cancer with a POLE mutation progresses frequently through the type I pathway despite its high-grade endometrioid morphology: a cohort study at a single institution in Japan.
Monsur M et al.
Medical Molecular Morphology, 2021
Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer.
Salem ME et al.
The Oncologist, 2020
Interpretation of somatic POLE mutations in endometrial carcinoma.
León-Castillo A et al.
The Journal of Pathology, 2020
POLE Mutation Characteristics in a Chinese Cohort with Endometrial Carcinoma.
Li Y et al.
Oncotargets and Therapy, 2020
Molecular profiling and molecular classification of endometrioid ovarian carcinomas.
Cybulska P et al.
Gynecologic Oncology, 2019
Next-Generation Sequencing.
Le Gallo M et al.
Advances in Experimental Medicine and Biology, 2017
The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.
Ahn SM et al.
Oncotarget, 2016
Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.
Wong A et al.
Gynecologic Oncology, 2016
Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.
Billingsley CC et al.
Cancer, 2015
JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations.
Ren Y et al.
Scientific Reports, 2013
DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer.
Church DN et al.
Human Molecular Genetics, 2013